{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:08:38Z","timestamp":1780488518777,"version":"3.54.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1124\/dmd.118.081364","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T14:35:22Z","timestamp":1533134122000},"page":"1420-1433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions"],"prefix":"10.1016","volume":"46","author":[{"given":"Luna","family":"Prieto Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Janz\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajsa P.","family":"Kanebratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Ericsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lundahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.081364_bib1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2125.1995.tb00001.x","article-title":"Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers","volume":"40","author":"Ahonen","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081364_bib2","first-page":"449","article-title":"Protein binding of itraconazole and fluconazole in patients with cancer","volume":"33","author":"Arredondo","year":"1995","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/jac\/43.2.305","article-title":"Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus","volume":"43","author":"Arredondo","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.118.081364_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2125.1991.tb03963.x","article-title":"Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes","volume":"32","author":"Back","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081364_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","article-title":"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin","volume":"54","author":"Backman","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081364_bib6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers","volume":"37","author":"Barone","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.118.081364_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/j.1875-9114.1998.tb03856.x","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers","volume":"18","author":"Barone","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.118.081364_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS J"},{"key":"10.1124\/dmd.118.081364_bib9","series-title":"Pharmacokinetic\u2013Pharmacodynamic Modeling and Simulation","author":"Bonate","year":"2011"},{"key":"10.1124\/dmd.118.081364_bib10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.ftd.0000150135.22645.ea","article-title":"Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients","volume":"27","author":"Buchkowsky","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.118.081364_bib63","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1124\/dmd.113.052241","article-title":"Drug Metabolites as Cytochrome P450 inhibitors: A Retrospective Analysis and Proposed Algorithm for Evaluation of the Pharmacokinetic Interaction Potential of Metabolites in Drug Discovery and Development","volume":"41","author":"Callegari","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib11","series-title":"Drug Safety Communication: FDA Limits Usage of Nizoral (Ketoconazole) Oral Tablets Due to Potentially Fatal Liver Injury and Risk of Drug Interactions and Adrenal Gland Problems","year":"2013"},{"key":"10.1124\/dmd.118.081364_bib12","series-title":"Guidance for Industry: Drug Interaction Studies\u2014Study Design, Data Analysis and Clinical Implications","year":"2017"},{"key":"10.1124\/dmd.118.081364_bib13","series-title":"Guidance for Industry: In Vitro Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies","year":"2017"},{"key":"10.1124\/dmd.118.081364_bib14","doi-asserted-by":"crossref","first-page":"W441","DOI":"10.1093\/nar\/gkp253","article-title":"IC50-to-Ki: a web-based tool for converting IC50 Ki values for inhibitors of enzyme activity and ligand binding","volume":"37","author":"Cer","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/dmd.118.081364_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/dmd.116.074138","article-title":"Intrinsic clearance assay incubational binding: a method comparison","volume":"45","author":"Chen","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40262-015-0352-5","article-title":"Development of a physiologically based pharmacokinetic model for itraconazole pharmacokinetics and drug\u2013drug interaction prediction","volume":"55","author":"Chen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.118.081364_bib17","series-title":"Press Release: European Medicines Agency Recommends Suspension of Marketing Authorisations for Oral Ketoconazole. EMA\/458028\/2013","year":"2013"},{"key":"10.1124\/dmd.118.081364_bib18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s11095-012-0918-y","article-title":"Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential","volume":"30","author":"Gertz","year":"2013","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.081364_bib19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.32.9.1310","article-title":"Pharmacokinetics of itraconazole following oral administration to normal volunteers","volume":"32","author":"Hardin","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1124\/dmd.118.081364_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","article-title":"The clinical pharmacokinetics of itraconazole: an overview","volume":"32","author":"Heykants","year":"1989","journal-title":"Mycoses"},{"key":"10.1124\/dmd.118.081364_bib21","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1124\/dmd.114.058784","article-title":"Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1","volume":"42","author":"Higgins","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1023\/A:1011077109233","article-title":"Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions","volume":"18","author":"Ishigam","year":"2001","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.081364_bib23","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"Jamei","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.081364_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib26","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0009-9236(97)90046-1","article-title":"Itraconazole increases plasma concentrations of quinidine","volume":"62","author":"Kaukonen","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2016.03.039","article-title":"N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry","volume":"1020","author":"Liang","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.118.081364_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jcph.562","article-title":"Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies","volume":"56","author":"Liu","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081364_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bdd.2107","article-title":"Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software","volume":"39","author":"Marsousi","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.118.081364_bib30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1023\/A:1012160419520","article-title":"Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence","volume":"14","author":"Marston","year":"1997","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.081364_bib31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1258\/acb.2010.010029","article-title":"A simple, sensitive high-performance liquid chromatography -ultraviolet method for the quantification of concentration and steady-state pharmacokinetics of itraconazole and hydroxyitraconazole","volume":"47","author":"Miura","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"10.1124\/dmd.118.081364_bib64","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1128\/AAC.00630-06","article-title":"Pharmacokinetics of Itraconazole and Hydroxyitraconazole in Healthy Subjects after Single and Multiple Doses of a Novel Formulation","volume":"50","author":"Mouton","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.118.081364_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1023\/A:1020926525495","article-title":"Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models","volume":"27","author":"Nestorov","year":"1999","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.118.081364_bib33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(98)90165-5","article-title":"Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole","volume":"63","author":"Neuvonen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0009-9236(96)90059-4","article-title":"The effect of ingestion time interval on the interaction between itraconazole and triazolam","volume":"60","author":"Neuvonen","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1258\/0004563053492711","article-title":"Determination of itraconazole in human plasma by high-performance liquid chromatography with solid-phase extraction","volume":"42","author":"Ohkubo","year":"2005","journal-title":"Ann Clin Biochem"},{"key":"10.1124\/dmd.118.081364_bib36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jps.2600680948","article-title":"Effect of altered plasma protein binding on apparent volume of distribution","volume":"68","author":"Oie","year":"1979","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.081364_bib37","first-page":"511","article-title":"The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"82","author":"Olkkola","year":"1996","journal-title":"Anesth Analg"},{"key":"10.1124\/dmd.118.081364_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199835060-00004","article-title":"Optimisation of itraconazole therapy using target drug concentrations","volume":"35","author":"Poirier","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.118.081364_bib40","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1002\/jps.21759","article-title":"Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods","volume":"98","author":"Poulin","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.081364_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/clpt.2012.65","article-title":"Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology","volume":"92","author":"Rostami-Hodjegan","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/bdd.1776","article-title":"Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay!","volume":"33","author":"Rostami-Hodjegan","year":"2012","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.118.081364_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","article-title":"Physiologically-based pharmacokinetics in drug development and regulatory science","volume":"51","author":"Rowland","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.118.081364_bib44","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/dmd.108.021477","article-title":"The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint Vmax Km): accuracy and robustness evaluated through experimental data and Monte Carlo simulations","volume":"37","author":"Sj\u00f6gren","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejps.2013.05.019","article-title":"In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim","volume":"49","author":"Sj\u00f6gren","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.118.081364_bib47","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/clpt.2010.119","article-title":"Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data","volume":"88","author":"Templeton","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib49","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1124\/dmd.30.12.1441","article-title":"Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors","volume":"30","author":"Tran","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12234","article-title":"Combining the \u2018bottom up\u2019 and \u2018top down\u2019 approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data","volume":"79","author":"Tsamandouras","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081364_bib51","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00007691-200608000-00007","article-title":"Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection","volume":"28","author":"Uno","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.118.081364_bib52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00558308","article-title":"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects","volume":"36","author":"Van Peer","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081364_bib53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.1994.184","article-title":"Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole","volume":"56","author":"Varhe","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.081364_bib54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/dmd.115.067744","article-title":"Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters","volume":"44","author":"Vermeer","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/j.1552-4604.1996.tb04251.x","article-title":"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents","volume":"36","author":"von Moltke","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.118.081364_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejpb.2012.05.008","article-title":"Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model","volume":"82","author":"Wagner","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1124\/dmd.118.081364_bib57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.chroma.2005.10.030","article-title":"High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry","volume":"1102","author":"Wan","year":"2006","journal-title":"J Chromatogr A"},{"key":"10.1124\/dmd.118.081364_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0773.1999.tb00085.x","article-title":"\u03b1-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole","volume":"85","author":"Wang","year":"1999","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/dmd.118.081364_bib59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.32.2.259","article-title":"Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites","volume":"32","author":"Wang","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0090-9556(24)14917-3","article-title":"Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver","volume":"27","author":"Yamano","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.081364_bib61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002130050715","article-title":"Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam","volume":"139","author":"Yasui","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/dmd.118.081364_bib62","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1248\/cpb.48.798","article-title":"Absorption, first-pass metabolism, and disposition of itraconazole in rats","volume":"48","author":"Yoo","year":"2000","journal-title":"Chem Pharm Bull (Tokyo)"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624055788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624055788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.081364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:36:49Z","timestamp":1739903809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624055788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0090955624055788"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.081364","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.081364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}